Our Mission
Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.
Spotlight
Lead Candidate, QBI-139
QBI-139 is an EVade™ Ribonuclease (with ~95% sequence identity with a protein made in the human pancreas) under development by Quintessence Biosciences. In pre-clinical disease models, QBI-139 showed an exceptional safety profile and outstanding tumor growth inhibition in vivo against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. |
Latest News
10.06.2008Quintessence
Biosciences, Inc. Awarded Federal Contract (PDF)Quintessence
Biosciences, Inc.announced the receipt of a Phase 1 Small Business
Innovation Research contract from the National Cancer Institute
to support the development of next generation drugs based on
the EVade™ Ribonuclease technology.
04.15.2008 Madison
biotech company happy to ride the coattails of competitor (link)
The novel therapies being developed by both companies target
RNA in cancer cells. While current anti-cancer therapies mostly
target either the DNA or specific proteins in cancer cells,
RNA, which is produced by the genes and then directs the production
of a cell's proteins, is an untapped target for killing cancer
cells.
02.18.2008Quintessence
Biosciences Selected as Feature Company in University Research
Park Story(link)
NBC15 reported on Hi Tech neighbors inMadison and featured Quintessence
Biosciences as one of the most promising companies in the area.
|
